Wells Fargo analyst Eva Fortea Verdejo raised the firm’s price target on Bicara Therapeutics (BCAX) to $16 from $11 and keeps an Equal Weight rating on the shares. The firm says Monday’s update provides further clarity on this year’s catalyst path for Bicara. While ASCO updates could be informative, Wells believes the stock-moving event is ficera’s interim readout in HNSCC happening in mid-2027.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAX:
- Buy Rating Backed by Ficerafusp Alfa Milestones and Strong Cash Runway Supporting $42 Target Price
- Bicara Therapeutics price target raised to $16 from $14 at Goldman Sachs
- Morning Movers: Sysco dips following deal to acquire Jetro Restaurant Depot
- Bicara Therapeutics reports Q4 EPS (68c), consensus (65c)
- BofA starts Bicara Therapeutics with a Buy on head and neck cancer potential